Clinical trial
Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are…
NCT00079001 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00079001 |
|---|---|
| Title | Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases |
| Official title | A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH SWOG Cancer Research Network Eastern Cooperative Oncology Group NCIC Clinical Trials Group Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Metastatic Cancer, Prostate Cancer |
| Intervention type | Dietary Supplement, Drug, Other |
| Interventions | zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D |
| Enrollment | 645 |
| Start date | Jan 1, 2004 |
| Primary completion | Jul 1, 2012 |
| Completion | Oct 1, 2014 |
| First posted | Mar 9, 2004 |
| Last update posted | May 12, 2020 |
| Countries | Canada, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: